LeonaBio (LONA) Preferred Stock Liabilities (2019 - 2020)
LeonaBio (LONA) reported Preferred Stock Liabilities of $92.5 million for Q2 2020, up 442.71% on a QoQ basis from $17.1 million in Q4 2019.
LeonaBio (LONA) has 2 years of Preferred Stock Liabilities data on file, last reported at $92.5 million in Q2 2020.
- Quarterly Preferred Stock Liabilities changed N/A year-over-year to $92.5 million in Q2 2020, while the trailing twelve-month figure through Jun 2020 was $92.5 million (changed N/A YoY) and the FY2019 annual result came in at $17.1 million, changed N/A from the prior year.
- Preferred Stock Liabilities climbed to $92.5 million in Q2 2020 per LONA's latest filing, from $17.1 million in the prior quarter.
- Across five years, Preferred Stock Liabilities topped out at $92.5 million in Q2 2020 and bottomed at $17.1 million in Q3 2019.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | - |
| 10 | LeonaBio | 181.52 Mn | 113.84 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2020 | 92.54 Mn |
| Dec 31, 2019 | 17.05 Mn |
| Sep 30, 2019 | 17.05 Mn |